SENNI, MICHELE

SENNI, MICHELE  

DIPARTIMENTO DI MEDICINA E CHIRURGIA (SCHOOL OF MEDICINE AND SURGERY)  

Mostra records
Risultati 1 - 20 di 358 (tempo di esecuzione: 0.031 secondi).
Titolo Tipologia Data di pubblicazione Autori File
The Therapy and Management of Heart Failure with Preserved Ejection Fraction: New Insights on Treatment 01 - Articolo su rivista 2024 Limonta, RMerlo, AGori, MGiannattasio, CSenni, MD'Elia, E +
Haemodynamic validation of the three-step HFA-PEFF algorithm to diagnose heart failure with preserved ejection fraction 01 - Articolo su rivista 2023 Baratto C.Villella F.Muraru D.Tomaselli M.Gavazzoni M.Badano L.Senni M.Parati G.Caravita S. +
Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin 01 - Articolo su rivista 2023 Senni M. +
One-year mortality in COVID-19 is associated with patients’ comorbidities rather than pneumonia severity 01 - Articolo su rivista 2023 Novelli L.Carobbio A.Senni M.Lorini F. L.Rambaldi A.Sironi S.Fagiuoli S.Barbui T. +
Pulmonary artery wedge pressure and left ventricular end-diastolic pressure during exercise in patients with dyspnoea 01 - Articolo su rivista 2023 Baratto, ClaudiaFaini, AndreaGallone, Gianluca PMuraru, DenisaSenni, MicheleBadano, LuigiParati, GianfrancoCaravita, Sergio +
Right Heart Adaptation to Exercise in Pulmonary Hypertension: An Invasive Hemodynamic Study 01 - Articolo su rivista 2023 Baratto C.Caravita S.Faini A.Perego g. B.Senni M.Muraru D.Badano LParati G. +
Shedding Light on Latent Pulmonary Vascular Disease in Heart Failure With Preserved Ejection Fraction 01 - Articolo su rivista 2023 Caravita S.Baratto C.Filippo A.Soranna D.Zambon A.Perego G. B.Muraru D.Senni M.Badano L. P.Parati G. +
Uncertainties in cardiovascular risk factors: sodium-glucose cotransporter 2 inhibitors for all diabetic patients with high cardiovascular risk and in all patients with renal insufficiency, regardless of albuminuria? Glucagon-like peptide-1 receptor agonists as a weapon against obesity? [Incertezze nei fattori di rischio cardiovascolare: inibitori del cotrasportatore sodio-glucosio di tipo 2 per tutti i pazienti diabetici ad elevato rischio cardiovascolare e per tutti i pazienti con insufficienza renale indipendentemente dall’albuminuria? Agonisti del recettore del glucagon-like peptide-1 come arma contro l’obesità?] 01 - Articolo su rivista 2023 Trevisan R.Senni M. +
A 57-year-old man with rapidly progressive pulmonary hypertension 01 - Articolo su rivista 2022 Novelli LLorini FLSenni M +
Angiotensin–neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure 01 - Articolo su rivista 2022 Senni M. +
Antecedent use of renin-angiotensin system inhibitors is associated with reduced mortality in elderly hypertensive Covid-19 patients 01 - Articolo su rivista 2022 Ghirardi, AriannaGavazzi, AntonelloTrevisan, RobertoNovelli, LucaLorini, Ferdinando LFagiuoli, StefanoParati, GianfrancoSenni, Michele +
Association between inhibitors of the renin-angiotensin system and lung function in elderly patients recovered from severe COVID-19 01 - Articolo su rivista 2022 Gori, MauroGhirardi, AriannaD'Elia, EmiliaGavazzi, AntonelloCarobbio, AlessandraTrevisan, RobertoNovelli, LucaLorini, Ferdinando LFagiuoli, StefanoBarbui, TizianoRizzi, MarcoSironi, SandroSenni, Michele +
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial 01 - Articolo su rivista 2022 Senni M. +
Can we improve the accuracy of electrocardiographic algorithms for accessory pathway location in children? 01 - Articolo su rivista 2022 Senni M. +
Characterization of compliance phenotypes in COVID-19 acute respiratory distress syndrome 01 - Articolo su rivista 2022 Bianchi I.Gandini L.Fagiuoli S.Senni M.Brambillasca P. +
Combined Role of Troponin and Natriuretic Peptides Measurements in Patients With Covid-19 (from the Cardio-COVID-Italy Multicenter Study) 01 - Articolo su rivista 2022 Senni M. +
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial 01 - Articolo su rivista 2022 Senni M. +
Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial 01 - Articolo su rivista 2022 Senni M. +
Experience of a pediatric electrophysiology clinic during the COVID-19 pandemic 01 - Articolo su rivista 2022 Senni M. +
Frequency, characteristics, and outcome of patients with COVID-19 pneumonia and "silent hypoxemia" at admission: a severity-matched analysis 01 - Articolo su rivista 2022 Novelli, LucaGhirardi, AriannaBeretta, MartaSenni, MicheleLorini, Ferdinando LGavazzi, AntonelloSironi, SandroFagiuoli, Stefano +